Metraipolis › archive › dc_2e7bc183e497
Ganaxolone, an approved therapy for CDKL5-deficiency disorder, is an inhibitor of PTP1B — Europe PMC PMID:42167577
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42167577
- DOI
- 10.1016/j.jbc.2026.113178
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-01T13:18:49.670Z
- SHA-256 of the archived text
3652ae5e52350dc8429449db6bf6175737eab84541d38f1f6b4f93dd2da0c6ea- Stable URL of this page
https://metraipolis.com/documento/dc_2e7bc183e497
How to cite
Ganaxolone, an approved therapy for CDKL5-deficiency disorder, is an inhibitor of PTP1B — Europe PMC PMID:42167577 — Europe PMC (en), https://europepmc.org/article/MED/42167577 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2e7bc183e497 (Metraipolis archive dc_2e7bc183e497, sha256 3652ae5e52350dc8429449db6bf6175737eab84541d38f1f6b4f93dd2da0c6ea)
BibTeX
@misc{dc2e7bc183e497,
title = {Ganaxolone, an approved therapy for CDKL5-deficiency disorder, is an inhibitor of PTP1B — Europe PMC PMID:42167577},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42167577},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2e7bc183e497; sha256 3652ae5e52350dc8429449db6bf6175737eab84541d38f1f6b4f93dd2da0c6ea},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42167577. Agents can read the archived copy with the MCP tool read_document.